Condition category
Nutritional, Metabolic, Endocrine
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting

Plain English Summary

Not provided at time of registration

Trial website

Contact information



Primary contact

Dr Rajeshwar Mookerjee


Contact details

Department of Hepatology
Royal Free Hospital
Pond Street
United Kingdom
+44 (0)207 433 2874

Additional identifiers

EudraCT number

2010-023241-29 number

Protocol/serial number


Study information

Scientific title

A pilot study to evaluate the safety, tolerability and efficacy of obeticholic acid (INT-747) for the treatment of portal hypertension



Study hypothesis

1. Obeticholic acid (OCA) is safe and tolerated in patients with cirrhosis and portal hypertension
2. Obeticholic acid (OCA) will reduce the Hepatic Venous Pressure Gradient (HVPG) in patients with portal hypertension

Ethics approval

National Research Ethics Service (NRES) North London REC 3 Committee approval granted on:
10 Dec 2010 (Final Protocol)
01 Mar 2011 (Amendment 1)
05 April 2011 (Amendment 2)
02 December 2011 (Amendment 3)

Study design

Pilot open label single centre study

Primary study design


Secondary study design

Non randomised study

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet


Portal hypertension in patients with alcoholic cirrhosis of the liver


1. Physical Examination
2. Vital signs
3. 12 Lead electrocardiogram (ECG)
4. Blood sampling and analysis – peripheral and hepatic blood samples
5. Urine collection and analysis
6. Hepatic vein catheterisation to measure HVPG and other hepatic haemodynamic measures (efficacy cohort only)

Intervention type



Not Applicable

Drug names

Obeticholic acid (OCA)

Primary outcome measures

1. Safety and tolerability as measured and assessed throughout the study by monitoring adverse experiences, clinical laboratory values in blood and measures of blood pressure and heart rate, all at baseline, Day 4, Day 7 and at follow up after 2-4 weeks and ECG at baseline and Day 7
2. Portal hypertension measured at baseline and Day 7 by HPVG. Outcome measure of a reduction of ≥15% at Day 7 compared to baseline or a reduction to <12 mmHg

Secondary outcome measures

1. Hepatic haemodynamics including hepatic blood flow (measured from the concentration of indocynanine green in the hepatic venous blood vs peripheral venous blood using the Fick Principle) and intrahepatic resistance (fluoroscopic examination after catheterisation of the right hepatic vein following injection of contrast medium)
2. Liver function: measured by gamma glutamyl transpeptidase (GGT), alanine transaminase (ALT), alkaline phosphatase (ALP), albumin, prothrombin time and bilirubin (total and unconjugated)
3. Pharmacokinetics: measured by plasma drug and metabolite concentrations
4. Inflammation: measured by C-reactive protein

Overall trial start date


Overall trial end date


Reason abandoned


Participant inclusion criteria

1. Male or female age 18-70 years
2. History of alcoholic cirrhosis with clinical or radiological and biochemical evidence of cirrhosis
3. Evidence of early decompensated cirrhosis (Child-Pugh score ≥7 to ≤12)
4. Patients recruited into the cohort evaluation of efficacy must have significant portal hypertension defined as an HVPG ≥ 12 mmHg
5. Patients with large or grade 3 oesophageal varices as identified by endoscopy within 6 months of screening should be in an endoscopic band ligation program at the time of study entry
6. Female patients must be postmenopausal, surgically sterile, or if premenopausal, must be prepared to use at least one effective (≤1% failure rate) method of contraception during the course of the study and for 14 days after the end of dosing. Male patients with female partners of child bearing potential must be prepared to use at least one effective method of contraception with all sexual partners unless they have had a prior vasectomy. Effective methods of contraception are considered to be:
6.1. Condom (male or female)
6.2. Diaphragm, with spermicide
6.3. Hormonal (e.g. contraceptive pill, patch, intramuscular implant or injection)
6.4. Intrauterine device (IUD)
6.5. Vasectomy (partner)
7. Must be willing and able to give written informed consent and agree to comply with the study protocol

Participant type


Age group




Target number of participants

Up to 39, depending on number of cohorts studied (3 cohorts up to 39, 2 cohorts up to 26)

Participant exclusion criteria

1. Patients with co-existing disease including:
1.1. Significant organ failure defined as:
1.2. Respiratory: PaO2 < 8kPa
1.3. Renal: serum creatinine >150 μmol/L
1.4. Cardiovascular: haemodynamic requirement for inotropic support
1.5. Central nervous system (CNS): hepatic encephalopathy West Haven Criteria score >2
1.6. Decompensated cirrhosis with requirement for organ support
1.7. Concomitant hepatobiliary disease (except hepatitis B or C viral disease), e.g., gallstones, primary sclerosing cholangitis, primary biliary cirrhosis
1.8. Known or suspected hepatic or extra hepatic malignancy, unless adequately treated or in complete remission for ≥ 3 years
1.9. Concomitant pancreatitis
2. Use of treatments for hepatitis B or C virus within 12 months of randomisation, or anticipated use during the study
3. Use of the following drugs within 6 months of randomisation: Immuno-modulatory treatment (including azothiaprine, methotrexate, anti-TNF therapies)
4. Use of concomitant vasoactive drugs within 3 months of randomisation:
4.1. Beta blockers
4.2. Nitrates
4.3. Vasopressin or analogues
5. Use of the following drugs within 3 months of randomisation:
5.1. Systemic corticosteroids
5.2. Pentoxifylline
5.3. Potentially hepatotoxic drugs (including  methyl-dopa, sodium valproic acid, isoniazid, or nitrofurantoin)
5.4. Ursodeoxycholic acid (UDCA)
5.5. Known or suspected use of illicit drugs or drugs of abuse (allowed if medically prescribed or indicated)
6. Change in dose or regimen within 3 months of randomisation of:
6.1. Fibrates or statins
6.2. Angiotensin II receptor antagonist or angiotensin converting enzyme (ACE) inhibitor
7. Presence of human immunodeficiency virus (HIV)
8. If female: pregnant, lactating, or positive serum or urine pregnancy test
9. Body mass index (BMI) >40, or >35 with complications
10. Other concomitant disease or condition likely to significantly decrease life expectancy (e.g., moderate to severe congestive heart failure)
11. Any patient who has received any investigational drug or device within 4 months of dosing, or who is scheduled to receive another investigational drug or device during the course of this study

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Department of Hepatology, Royal Free Hospital
Pond Street Hampstead
United Kingdom

Trial participating centre

University Hospital Leuven (Universitat Ziekenhuis Leuven (UZL))
Dept Hepatology and Pancreaticobiliary Disorders Herestraat 49
B - 3000

Sponsor information


Intercept Pharmaceuticals Inc

Sponsor details

18 Desbrosses Street
New York
NY 10013
United States of America
+1 646 747 1000

Sponsor type




Funder type


Funder name

Intercept Pharmaceuticals Inc

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes

26/02/2016: No publications found, verifying study status with principal investigator